Fibrinogen Aα Thr312Ala Polymorphism Specifically Contributes to Chronic Thromboembolic Pulmonary Hypertension by Increasing Fibrin Resistance
Jifeng Li(Capital Medical University), Chen Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Na Cui(Soochow University), Yuanhua Yang(Capital Medical University), Jie Liu(Capital Medical University), Jun Wang(Wuhan University of Science and Technology), Yan Liang(Capital Medical University), Yuan Lin(Capital Medical University), Lan Zhao(Tianjin Fourth Central Hospital), Wei-Juan Zhang(Capital Medical University), Hui‐Li Gan(Capital Medical University), Suqiao Yang(Capital Medical University)
Cited by 36
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.7k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k